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Abstract
N,N-bisheteryl derivatives of dispirotripiperazine (DSTP) are a novel class of antiviral compounds with some of their representatives
very effectively inhibiting the replication of herpes simplex virus type 1 (HSV-1) in cell culture. Using one representative of these
compounds, the N,N-bis(1-oxido[1,2,5]oxadiazolo[3,4-d]pyrimidin-7-yl)-3,12-diaza-6,9-diazonia(5,2,5,2)dispirohexadecane dichloride
(DSTP 27), we here further tried to elucidate the molecular mechanisms responsible for the antiviral activity. The results from plaque
reduction assays under a variety of conditions suggest that inhibition of HSV-1 strain Kupka replication by DSTP 27 occurs at the level of
viral attachment by blockade of heparan sulfate (HS) structures on the cell surface that are used as viral receptors. In contrast to heparin
and pentosan polysulfate, pretreatment of cells with DSTP 27 resulted in efficient inhibition of viral adsorption and replication persisting
several hours after removal of the inhibitor. Specific binding of DSTP 27 to heparin was demonstrated in vitro. Titrations of gC-positive
and gC-negative pseudorabies virus (PrV) mutants on HS-positive and HS-negative cell lines confirmed that inhibitory action of DSTP 27
is strictly HS dependent. Aside from HSV-1 Kupka and PrV, DSTP 27 efficiently inhibits growth of several HSV-1 and HSV-2 strains,
among them aciclovir/foscarnet-resistant strains, human cytomegalovirus, human respiratory syncytial virus, and human immunodeficiency
viruses known to attach to the cell surface via HS.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The first essential step in virus infection is the binding of
viral attachment proteins to cell surface molecules. Among
the alphaherpesviruses, the attachment process of herpes
simplex virus type 1 and 2 (HSV-1 and HSV-2) and pseu-
dorabies virus (PrV) has been studied in detail. In HSV-1
and PrV, the attachment process can be dissected in two
separate steps (Karger and Mettenleiter, 1993; Shukla and
Spear, 2001). In the very first step, the virion loosely at-
taches to the cell surface by an interaction between the viral
glycoproteins C (gC) and, in the case of HSV-1 also gB, to
cell surface heparan sulfate proteoglycans (HSPG) (Karger
and Mettenleiter, 1996; Spear et al., 1992). Additionally,
entry of HSV-1 may be initiated by binding of viral gD to
3-O-sulfated HS (Shukla et al., 1999). Therefore, replication
of these herpesviruses is efficiently inhibited by heparin, a
soluble structural analog of HS, but also by a number of
other polyanionic compounds like polysulfates, polysulfon-
ates, polycarboxylates and negatively charged albumins
(Andrei et al., 1992; Baba et al., 1988; Herold et al., 1996;
Meerbach et al., 2001, Ramos-Kuri et al., 1996; Vaheri,
1964). These antiviral compounds were broadly used in
receptor studies to demonstrate the crucial role of HSPG in
virus attachment. However, from the viewpoint of therapeu-
tical application and mechanistic studies these substances
carry inherent disadvantages like high and variable molec-
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ular weights, high structural variability, and biological ori-
gin.
Recently, we described the structure-activity relationship
of a new class of highly antiherpetic compounds, the N,N-
bisheteryl derivatives of DSTP (Schmidtke et al., 2002),
which are active when added prior to the inoculation of
target cells with virus. We have now selected one represen-
tative dispirotripiperazine derivative, DSTP 27, for a more
detailed characterization of the inhibitory action of DSTP
27 on HSV-1 strain Kupka. Pseudorabies virus mutants
lacking glycoprotein C and L-cell mutants lacking HS were
included in the study to assay the DSTP 27 effects on
alphaherpesviruses in the absence of virus-HS interactions.
Our results suggest that DSTP 27 acts by blocking HS-
containing receptors on the cell surface. This was proven
both by an in vitro binding assay of DSTP 27 to immobi-
lized heparin, a structural analog of HS, and by virus-
binding assays. The finding that DSTP 27 inhibits replica-
tion of a number of other members of the herpesvirus family
as well as viruses from other families known to use HSPG
as receptor or coreceptor further confirms this conclusion.
Results
Effect of DSTP 27 during different stages of the viral life
cycle of HSV-1
Recently, we demonstrated the potent antiviral activity of
dispirotripiperazine derivatives against HSV-1 (Schmidtke
et al., 2002). As DSTP 27 was without effect on viral
replication when added to the cell culture after adsorption,
we analyzed the effect of DSTP 27 on the first steps of the
herpesvirus life cycle in detail. Cells and/or viruses were
exposed to the inhibitor before inoculation, during the ad-
sorption phase, during and after adsorption phase, or only
after the adsorption phase. These experiments were con-
trolled by treatment with heparin and pentosan polysulfate
(PPS). Heparin is broadly used as soluble HS analog in virus
receptor studies because there are no distinct characteristics
to separate HS and heparin based upon there structure (Liu
and Thorp, 2002). Like heparin, PPS is a well-characterized
inhibitor of HS-mediated viral adsorption.
Pretreatment of virions with DSTP 27 has no effect on
virus adsorption
The effect of DSTP 27 on HSV-1 virions was tested in
plaque reduction assays by preincubating virus stocks with
DSTP 27, heparin, or PPS. After dilution of the inhibitors
100-fold, a concentration that does not affect virus adsorp-
tion, the numbers of plaques formed by inhibitor-treated
virus suspensions were not reduced in comparison to the
untreated controls (Fig. 1). Surprisingly, incubation with
DSTP 27 and PPS but not with heparin led to enhanced
recovery of infectious virus (151 and 166%, respectively).
Pretreatment of cells with DSTP 27 but not with heparin
or PPS prevents HSV-1 adsorption to and replication in
GMK cells
Like heparin and PPS, DSTP 27 was effective when
added to the cell culture during the attachment phase at 4°C
and without effect when added thereafter demonstrating that
it inhibits HSV-1 adsorption (Fig. 1). However, results from
further experiments revealed clear differences in the mode
of action between the DSTP 27 and the two high molecular
weight inhibitors heparin and PPS. Whereas DSTP 27-
pretreated GMK cells were highly resistant to HSV-1 infec-
tion under our experimental conditions, GMK cells prein-
cubated with heparin or PPS remained fully sensitive to
infection. When the inhibitor was added 1 h before virus
Fig. 1. Differences in the modes of action among DSTP 27, heparin, and PPS. Modified plaque reduction assays on GMK cell monolayers were used to
compare the effect of DSTP 27 with that of heparin and PPS against HSV-1 during different stages of the viral life cycle. Of the respective inhibitor 25 g/ml
was added to cell-free virus, to cells before virus inoculation, during virus adsorption at 4°C, during and after virus adsorption, or only after adsorption. Mean
values and standard deviations of at least 3 independent experiments are shown.
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addition to cell culture, the 50% inhibitory concentration of
DSTP 27 (calculated from the mean dose-response curve of
3 PRA) was 3.7 M (2.1 g/ml). Prolongation of the pre-
incubation of cells with DSTP 27 from 1 up to 2, 3, or 4 h
did not improve the inhibitory effect (results not shown).
Interestingly, protection persisted if DSTP 27 was removed
from cell cultures before virus addition (Fig. 2). When the
compound was added for 1 h to cell culture, inhibitory
effects disappeared 4, 24, 48, and 72 h after washing away
DSTP 27 at 4, 20, 100, and 500 g/ml, respectively. These
results suggest a high-affinity occupation of cell surface-
binding sites preventing HSV-1 binding and, therefore, rep-
lication.
DSTP 27 binds to heparin in vitro
An in vitro binding assay of DSTP 27 to immobilized
heparin was used to show that DSTP 27 has heparin-binding
capability and that binding is specific for heparin. Heparin
acrylic beads were loaded with DSTP 27 and the concentration
of DSTP 27 in the supernatant of beads was monitored after
addition of varying concentrations of heparin or chondroitin
sulfate (CS), the other predominant glycosaminoglycan in
MDBK cells (Karger et al., 1998). Fig. 3 shows that binding of
DSTP 27 to heparin acrylic beads can be competed very
effectively with heparin at low concentrations, whereas effec-
tive concentrations of CS are about 1–2 logs higher.
DSTP 27 specifically interferes with HS-mediated
adsorption of PrV
The biological significance of the observed binding to
heparin in vitro was further investigated in virus-infected
Fig. 2. Persistence of the inhibitory effect of DSTP 27 on HSV-1 Kupka
after removal of the inhibitor. GMK cell monolayers were pretreated
without or with 4, 20, 100, and 500 g/ml of DSTP 27 for 1 h at 37°C.
Thereafter, the inhibitor was removed, and the cells were washed 3 times
and incubated in plain medium for the time indicated until virus infection.
The mean values of plaque reduction and standard deviations of three
experiments are shown.
Fig. 3. In vitro binding of DSTP 27 to immobilized heparin. Heparin beads were incubated with DSTP 27 and concentration in the supernatant was assayed
after addition of varying amounts of heparin (}) or chondroitin sulfate (). Amounts of DSTP 27 displaced by heparin or chondroitin sulfate were then
calculated. Five- to 10-fold higher concentrations of chondroitin sulfate were required to displace the same amounts of DSTP 27 compared to heparin,
demonstrating the specificity of heparin binding by DSTP 27. Mean values and standard deviations of 4 independent experiments are shown.
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cell culture. PrV was chosen for these tests because gC of
PrV is the only glycoprotein that interacts productively with
HS (Robbins et al., 1986). Therefore, in contrast to HSV-1,
gC-negative PrV mutants can be used to assay plaquing
efficiency in the absence of HS-mediated attachment. We
have used a pair of Kaplan strain-derived isogenic PrV
mutants: PrV-1112, which contains a galactosidase cassette
in the gG locus and, except from being gal, can be con-
sidered a quasi-wild-type PrV, and PrV-8411, which addi-
tionally is gC negative (Karger et al., 1995). Fig. 4A shows
a representative experiment for the determination of IC50
values of DSTP 27 for PrV-1112 and PrV-8411 on MDBK
cells. Up to concentrations of 1000 M, no effect on at-
tachment of the gC-negative mutant PrV-8411 was detect-
able, while inhibition of PrV-1112 was half-maximal at 17
M. Vice versa, infection of HS-negative L-cell variants
(gro2C and sog9) with PrV-112 could not be blocked with
DSTP 27 in contrast to HS-positive L-cells (Fig. 4B). No
significant difference in inhibitory potency of DSTP 27 was
detected between sog9 and gro2c cells. Taken together,
these experiments demonstrate that inhibition of PrV by
DSTP 27 strictly depends on a heparin-mediated interaction
of virus and cell. As the major function of gC in PrV is the
establishment of HS-mediated adsorption, and PrV-8411 is
not affected by DSTP 27, we assume that HS is the only
target of DSTP 27.
Direct evidence for the inhibition of virus binding by
DSTP27 was obtained by an attachment assay performed
with gradient-purified radiolabeled PrV-1112 at 0°C. Prein-
cubation with DSTP27 resulted in a concentration-depen-
dent inhibition of virus binding (Table 1). A maximum
inhibition of approximately 95% was observed, which cor-
responds well to the titration experiments. As the experi-
mental conditions allow only virus binding but not the
following steps of viral entry, the inhibitory effect of
DSTP27 can be clearly attributed to the interference with
virus binding.
Antiviral activity against other herpesviruses
Plaque formation of strains of HSV type 1 and type 2 was
strongly inhibited by DSTP 27 if the compound was added
immediately before virus inoculation (Table 2). The IC50 for
all herpes simplex viruses tested was in the range of 8.4–
20.4 M and no differences were observed between aciclo-
vir- and phosphonoformic acid (PFA)-sensitive or ACV-
and PFA-resistant HSV strains. In addition, the IC50 for
HCMV determined in cell ELISA was in good accordance
with these data. The cell ELISA was performed in untreated
and compound-treated 2-day-old MRC-5 cells which were
inoculated with HCMV at a MOI of 0.02. Four days after
infection the pp65 antigen of HCMV was detected with a
virus-specific monoclonal antibody. Horseradish peroxi-
dase-labeled goat anti-mouse IgG was used as the secondary
antibody for detection of bound monoclonal antibody. En-
zyme activity in untreated and compound-treated infected
cells was quantified spectrometrically after addition of OPD
substrate using a microplate reader.
In contrast to the HSV results, neither DSTP 27 nor
heparin affected the VZV-induced cytopathic effect in pri-
mary thyroid cells (Table 2). Furthermore, DSTP 27 did not
inhibit the EBV-induced transformation of cord blood lym-
phocytes, regardless of whether DSTP 27 was added to the
cells 1 or 24 h before infection, together with the virus, and
1 or 24 h after infection. Samples of uninfected control
cells, of untreated infected cells, and of cells treated for 1 h
before infection with 100 g/ml are shown in Figs. 5A, B,
and C, respectively. In cultures with and without DSTP 27
at various concentrations 10–16 transformed colonies were
observed. All colonies were positive for EBV nuclear anti-
gen by immunofluorescence. Receptor blockade by EBV
P3HR-1 (transformation incompetent) before addition of
EBV B95-8 (transformation competent) resulted in com-
plete inhibition of virus-induced transformation (Fig. 5D).
In contrast to EBV B95-8, EBV P3HR-1 is deleted in the
EBNA-2 gene and, therefore, unable to induce transforma-
tion in lymphocytes. The results shown in Fig. 5D demon-
strate that transformation can be inhibited under these ex-
perimental conditions. Whereas uninfected and EBV P3HR-
1-infected cord blood lymphocytes died (Figs. 5A and D),
the EBV B95-8-transformed blood lymphocytes began to
proliferate 5 days after infection both in the presence and in
the absence of compound DSTP 27 (Figs. 5B and C).
Antiviral activity against other viruses using HS as
receptor or coreceptor
As virus attachment to HS residues on the cell surface is
found in a number of other virus families than the herpes-
viruses, the antiviral effect of DSTP 27 on paramyxoviruses
and retroviruses was tested. The results presented in Table
3 demonstrate that DSTP 27 is also a potent inhibitor of
HRSV and HIV-1 replication. However, a wide range of
sensitivities was observed. Among the isolates tested,
HIV-1 6S and HIV-1 DPS were most sensitive for the
inhibitory action of DSTP 27 with IC50 values of 1.37 and
1.17 M, respectively. In contrast to these two HIV strains,
HIV-1 RF was 100-fold less sensitive to DSTP-27 (IC50
value of 150 M).
Discussion
In this study the molecular mechanism of the inhibitory
action of DSTP 27, a representative of a new class of
antiherpetic compounds with dispirotripiperazine structure
(Schmidtke et al., 2002), was investigated. DSTP 27 has no
virucidal effect but inhibits virus attachment by blockade of
cellular virus receptors. Preincubation of target cells, but not
preincubation of virus particles with DSTP 27 led to drastic
reduction of HSV-1 replication (Fig. 1). The virus receptors
involved were identified as HS containing cellular structures
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by 3 lines of evidence: (1) In vitro binding of DSTP 27 to
heparin acrylic beads was effectively antagonized by solu-
ble heparin whereas competition with soluble CS was much
weaker. (2) Biological significance of this in vitro effect was
demonstrated with two isogenic PrV mutants one of which
(PrV-1112) is gC positive and the other (PrV-8411) is gC
Fig. 4. Binding of DSTP 27 to cells inhibits gC-mediated interaction of PrV with HSPG. (A) MDBK cells were inoculated with dilutions of PrV-1112 and
PrV-8411 producing approximately 100 plaques in 24-well cell culture dishes on ice in the presence of varying concentrations of DSTP 27. After removal
of the inoculum, cells were incubated at 37°C and plaque yield was estimated after 48 h. Whereas gC-positive PrV-1112 was effectively inhibited, no
inhibition of gC-negative PrV-8411 could be observed in the concentration range tested. Mean values and standard deviations of 4 independent experiments
are shown. (B) Titers of PrV-1112 were estimated on L-cells, and on two HS negative L-cell derivatives, namely gro2C and sog9 cells, in the presence or
absence of heparin (10 g/ml) and DSTP (40 g/ml). Inhibitors were added to the virus inoculum on ice and after 1 h, temperature was shifted to 37°C, and
plaque yield was estimated after 48 h. Titers on untreated cells were taken as 100% values and relative titers of 4 independent experiments are shown. Heparin
and DSTP 27 both efficiently reduced viral titers on HS-positive L-cells but were without effect on gro2C or sog9 cells, demonstrating that the antiviral
activity of DSTP 27 depends on the presence of HS on the cell surface.
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negative. In PrV, but not in HSV-1 (Herold et al., 1994) gC
is the only glycoprotein productively interacting with HS
(Mettenleiter et al., 1990). In contrast to PrV-1112, PrV-
8411 was not notably inhibited by DTSP 27, showing that in
the absence of gC-HS interaction DSTP 27 is without effect.
(3) DSTP 27 inhibited PrV-1112 on L-cells to the same
degree as heparin but, as heparin, it was without effect on
HS-negative L-cell variants. Taken together, these results
demonstrate that the inhibitory action of DSTP 27 on viral
growth requires the presence of HS on the cell surface and
a HS-binding viral attachment protein. Our studies were
further expanded to other herpesviruses from the alphaher-
pes (HSV-2, VZV), betaherpes (HCMV), and gammaherpes
(EBV) subfamilies. HSV-2 was also inhibited by DSTP 27,
although IC50 values were slightly higher than for HSV-1.
This could be explained by the different affinities of gC-1
and gC-2 for structural features of HS (Herold et al., 1995,
1996). Notably, resistance to other antiherpetic drugs like
foscarnet or aciclovir had no influence on the susceptibility
of HSV-1 and HSV-2 strains to inhibition by DSTP 27. The
fact that replication of HSV-1 could not be totally sup-
pressed by DSTP 27 is in accordance with the nonessential
character of this glycoprotein in the alphaherpesviruses that
have been studied. Alternative HS-independent attachment
pathways have been discussed for HSV-1 and PrV (Karger
et al., 1995; Montgomery et al., 1996; Warner et al., 1998).
It is noteworthy that exposure of target cells to DSTP 27
protects against HSV-1 even after removal of the inhibitor,
suggesting that the affinity of DSTP 27 for virus receptors is
very high.
In contrast to previously published results obtained in
human melanoma cells (Cohen and Seidel, 1994), neither
Table 2
Anti-herpesvirus activity
Virus strains Cells 50% inhibitory activity (M)
Aciclovir PFAa DSTP 27
HSV-1 Kupka GMK 9.3 91.7 8.1
HSV-1 K1 GMK 5.3 83.3 8.6
HSV-1 K1r GMK 945.4 109.0 8.4
HSV-1 AngPr GMK 1445.4 601.0 9.8
HSV-2 US GMK 115.0 222.3 20.4
HSV-2 P GMK 728.2 88.3 10.2
Ganciclovir PFAa DSTP 27
HCMV MRC-5 7.78 56.0 12.3
BVDUb heparin DSTP 27
VZV Primary thyroid
cells
0.06 not active not active
a Phosphonoformic acid.
b (E)-5-(2-Bromovinyl)-2-deoxyuridine.
Table 1
Attachment of PrV-1112 to MDBK cells after pretreatment with
DSTP27
DSTP 27
(g/ml)
mean % of
binding
Standard
deviation
0 100.0  8.93
0.08 113.8  7.88
0.80 62.3  12.7
8.00 2.8  1.25
80.00 4.3  1.84
Fig. 5. DSTP 27 does not affect EBV-induced transformation. (A) Sixteen-
day-old nonproliferating cord blood lymphocytes. (B) Proliferating foci of
cord blood lymphocytes transformed by EBV B95-8 at Day 42 p.i. (C)
Proliferating foci of cord blood lymphocytes transformed by EBV B95-8 in
presence of 100 g/ml compound DSTP 27 (added 1 h before infection) at
Day 16 p.i. (D) Inhibition of EBV B95-8-induced transformation by EBV
P3HR-1-mediated receptor blockade: nonproliferating cord blood lympho-
cytes after infection with transformation-incompetent EBV P3HR-1 cells
before addition of transformation-competent EBV B95-8 at Day 42 p.i.
Magnification 130.
Table 3
Antiviral activity of DSTP 27 against other viruses using heparan sulfate
as receptor or coreceptor
Virus strain Cells CC50a
(M)
IC50b
(M)
TIc
(CC50/IC50)
HIV-1 6S MT-2 98.2 1.4 71.4
HIV-1 IIIB MT-4 200.0 5.7 35.0
HIV-1 RF CEM-SS 197 150.0 1.3
HIV-1 N119 MT-4 200.0 31.7 6.3
HIV-1 DPS MT-4 200.0 1.2 170.0
HIV-1 A-17 MT-2 79.1 4.7 16.7
HIV-1 A-17 MT-4 200.0 33.7 5.9
HIV-2 ROD CEM-SS 200.0 13.3 15.0
SIV MAC 251 MT-4 200.0 6.3 31.5
HRSV GMK 1756.2 7.5 110.4
a 50% cytotoxic concentration.
b 50% inhibitory concentration.
c Therapeutic index.
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heparin nor DSTP 27 inhibited VZV-induced cytopathic
effects in thyroid cells that were used in our study, suggest-
ing that sensitivity to heparin and DSTP 27 is determined by
cell-specific HSPG expression (Immergluck et al., 1998;
Turnbull et al., 2001). The results obtained for HCMV
(inhibition by DSTP 27) and EBV (no inhibition by DSTP
27) confirm previous results (Kari and Gehrz, 1992; Shukla
and Spear, 2001) obtained with heparin.
Respiratory syncytial viruses have also been shown to at-
tach to HS structures on the cell surface (Feldman et al., 2000;
Hallak et al., 2000; Karger et al., 2001) with the HS-binding
capacity residing in the envelope glycoproteins G, the attach-
ment protein, and F, the fusion protein. Thus it was not unex-
pected that HRSV was sensitive to inhibition by DSTP 27. So
far it is not known if G and F proteins interact with different
subsets of HS or if DSTP 27 specifically antagonizes G- or
F-mediated interactions with cell surface HSPG.
In contrast to HSV where IC50 values were in the same
range for all the strains tested (8.2 to 20.4 M), inhibition
of HIV was strongly strain-dependent with IC50 values
ranging from 150 M (HIV-1 RF on CEM-SS) to 1.2 M
(HIV-1 6S on MT-2). For the HIV-1 strain A17, IC50 values
determined in different cell lines varied between 33.7 and
4.7 M, suggesting the dependence of antiviral action on
the HS expression pattern of the target cells. Variation of
IC50 values obtained for different virus strains on the cell
line MT-4 most likely reflect differential coreceptor usage,
which is a well-known phenomenon in HIV replication
(O’Brien and Moore, 2000). In contrast to herpesviruses, we
have no information on structural features of HS supporting
HIV attachment. Virus strain and cell specificity of the
inhibitory effect together with the capability to form very
stable bonds with some virus receptors or coreceptors (see
above) and the fact that it is a chemically defined low
molecular weight compound could make DSTP 27 a valu-
able tool for the characterization of virus-cell interactions.
In summary, DSTP 27 is the first synthetic low molecular
weight compound shown to prevent attachment of HSV-1
Kupka and pseudorabies virus by binding to cell surface mol-
ecules containing HS. It also efficiently inhibits a number of
other HSV-1 and HSV-2 strains including aciclovir- and fos-
carnet-resistant strains, HCMV, HRSV, and some HIV vari-
ants using HSPG as receptor or coreceptor. The observed
molecular mechanism differs from the antiviral drugs used to
date as well as from polyanionic compounds used as soluble
HS receptor analogs. The persistance of protection may be an
important advantage for use in HS receptor studies and further
investigations on the antiviral activity of DSTP in vivo.
Materials and methods
Compounds
The synthesis of the N,N-bis(1-oxido[1,2,5]oxadiazolo
[3,4-d]pyrimidin-7-yl)-3,12-diaza-6,9-diazonia(5,2,5,2)dispir-
hexadecane dichloride (DSTP 27; MW, 569.4) was described
by Schmidtke et al. (2002). The structure of DSTP 27 is shown
in Fig. 6. Aciclovir (ACV; Sigma, Germany) and phosphono-
formic acid (PFA; Sigma), ganciclovir (GCV, purchased as
cymeven; Hoffmann La Roche AG, Germany) and (E)-5-(2-
bromovinyl)-2-deoxyuridine (BVDU; purchased as brivudin;
Berlin Chemie, Germany) were used as positive control com-
pounds in the antiviral assays. In addition, pentosan polysulfate
(PPS; bene Arzneimittel GmbH, Germany) and bovine lung
heparin (heparin; Sigma) were used as reference compounds in
antiviral assays studying the mechanism of activity. Stock
solutions of the compounds in water (10 mg/ml) were stored at
4°C and diluted in cell culture medium on the day of use.
Cells and viruses
GMK cells (green monkey kidney cells; Schaper &
Bru¨mmer, Salzgitter, Germany) were grown in Dulbecco’s
modified MEM/E (DMEM, Sigma) and the human lung
fibroblasts (MRC-5; ECACC No. 84101801) as well as the
primary human embryonal lung fibroblasts in MEM/E (Sig-
ma) supplemented with 10% fetal bovine serum (FBS;
Greiner, Germany), 100 U/ml penicillin, and 100 g/ml
streptomycin. The test medium contains 5 or 20% FBS for
herpes viruses or human respiratory syncytial virus
(HRSV), respectively. The thyroid cells were grown in
HLA (GIBCO, Germany)/L15 (Biochrom, Germany)/199
Hanks (Biochrom) in a 5:1:4 ratio supplemented with 10%
FBS. The lymphoblastoid cell lines B95-8 and P3HR-1
were passaged in RPMI 1640 medium (Biochrom), 10%
FBS, 1% L-glutamine, 100 U/ml penicillin, and 100 g/ml
streptomycin. Peripheral blood mononuclear cells were iso-
lated from EDTA-umbilical cord blood by Ficoll-Hypaque
density gradients and cultivated in RPMI 1640 medium
containing 20% FBS. L-cells and L-cell derivatives defi-
cient in heparan sulfate synthesis (gro2C cells; Gruenheid et
al., 1993) or glycosaminoglycan synthesis (sog9 cells; Ban-
field et al., 1995) were kindly provided by F. Tufaro, Car-
negie Institution of Washington, USA, and grown in
DMEM supplemented with 10% FBS.
The following viruses were used: HSV-1 Kupka, HSV-1
K1, HSV-1 K1r, HSV-1 AngPr (kindly provided by W.
Hampl, University Ulm, Germany) (Pavic et al., 1997),
HSV type 2 US (HSV-2 US), HSV-2 P, the human cyto-
megalovirus strain AD169 (HCMV, kindly provided by
Prof. Mach, University Erlangen, Germany), varizella-zos-
ter virus OKA (VZV; ATCC VR-795), Epstein-Barr virus
(EBV), HRSV, PrV-1112, and PrV-8411, an isogenic gC-
Fig. 6. Structure of DSTP 27.
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negative mutant derived from PrV-1112 (Karger et al.,
1995). Stocks of herpes viruses and HRSV were prepared in
GMK cells. PrV was propagated in swine kidney cells,
HCMV in MRC-5 cells, and VZV in primary human em-
bryonal lung fibroblasts. Titers of virus stocks were deter-
mined by plaque assay on the respective cell monolayers.
EBV stocks were harvested from supernatants of virus-
producing lymphoblastoid cell lines B95-8 and P3HR-1
(EBV B95-8 and EBV P3HR-1, respectively). The tumor pro-
moter 12-O-tetradecanoylphorbol-13-acetate (TPA, Sigma)
was added at a concentration of 20 ng/ml in P3HR-1 cell
culture to induce virus production. EBV P3HR-1 does not
contain the EBNA-2 gene necessary for transformation.
Aliquots of virus stocks were stored at 80°C until use.
Plaque reduction assays with herpesviruses and HRSV
The plaque reduction assay (PRA) was performed as
described previously (Schmidtke et al., 2001). Briefly, after
removal of the cell culture medium, GMK cell monolayers
in 6-well plates (FALCON 3046) were inoculated with
approximately 100 plaque forming units (pfu) of the respec-
tive herpesvirus or HRSV in test medium in the absence or
presence of serial twofold dilutions of the test compounds.
After adsorption at 37°C for 1 h, the inoculum was aspirated
and 2 ml of the respective test medium containing 0.4% agar
and the respective concentrations of the drug were added.
Three untreated virus controls and one uninfected untreated
cell control were included in all assays. Each inhibitor
concentration was tested in duplicate. The cell cultures were
incubated until plaques appeared and then fixed and stained
with a solution of 0.4% crystal violet in a mixture of for-
malin (3% v/v) and ethanol (1.67% v/v) in water overnight.
Plaques were counted over a light box after removal of the
agar overlay.
To test the effect of inhibitors on cell-free virus, PRA
was modified as follows: 106 pfu of HSV-1 Kupka were
incubated with or without the inhibitors in test medium for
6 h at 37°C. Then the mixture was diluted 1:100 to obtain
noneffective inhibitor concentrations and added to confluent
cell monolayers. After a 1 h incubation at 37°C the inocu-
lum was replaced by agar-containing test medium without
inhibitor.
Inhibition of viral adsorption by DSTP 27, heparin, and
PPS was tested at 4°C, a temperature at which viruses bind
to, but do not enter, host cells. In one set of experiments,
GMK cells were preincubated with or without inhibitor for
1 h at 4 or 37°C and washed three times before addition of
virus. After exposure of the cell monolayers to virus, the test
was continued as described above. In a second set of ex-
periments GMK cells were inoculated with HSV-1 Kupka
in test medium in the presence or absence of inhibitors for
2 h at 4°C. Then the virus inoculum and the inhibitors were
removed, and the cells were overlaid with or without the
inhibitor.
To show the effect of DSTP 27 on viral replication after
virus attachment, the compound was added together with
the agar overlay after cells had been inoculated at 4°C for
2 h. Titration of PrV on MDBK cells and L-cell derivatives
were carried out in 6-well cell culture plates. Cell mono-
layers were inoculated with serial 10-fold dilutions of the
virus in the presence or absence of the respective inhibitor
for 1 h at 37°C. The inoculum was removed and the num-
bers of plaques were determined after further incubation at
37°C for 48 h and staining with X-Gal solution (Sanes et al.,
1986).
Studies on the influence of time of removal of DSTP 27
on anti-HSV-1 activity
Two-day-old confluent GMK cell monolayers grown in
12-well plates were incubated with 0.5 ml of test medium
containing 4, 20, 100, and 500 g DSTP 27/ml for 1 h at
37°C. After three washings with 0.5 ml serum-free DMEM,
0.5 ml cell culture medium was added for 1, 4, 8, 12, 24, 48,
or 72 h before approximately 50 pfu of HSV-1 Kupka were
inoculated. Afterward, the plaque assay was performed as
described above.
In situ ELISA for evaluation of antiviral compounds
effective against human cytomegalovirus
Human lung fibroblasts (MRC-5) were plated at a den-
sity of 1.5  104 cells per well in a 96-well microtiter plate.
After 48 h, cells were inoculated with HCMV at a multi-
plicity of infection (MOI) of 0.02 immediately after the
addition of various concentrations of the inhibitor. After 2 h
incubation at 37°C, the supernatant was replaced by me-
dium containing the inhibitor. Four days after infection cells
were fixed (100% methanol) and reacted with a primary
antibody specific for the pp65-antigen of HCMV. Then the
cells were reacted with goat-anti-mouse immunglobulin G
conjugated to horseradish peroxidase-labeled secondary an-
tibody and developed with o-phenylenediamine (OPD) sub-
strate.
Determination of antiviral activity against VZV
Thyroid cells were seeded at a density of 2  104
cells/well in 96-well plates. The cells were either incubated
for 3 days to form a monolayer and then treated with
inhibitors and infected or the inhibitors were added imme-
diately to the suspension culture in different concentrations
(1–128 g/ml) in a volume of 50 l followed by infection
with 50 l of a virus stock containing 40-fold the TCID50.
After an incubation period of 11 days (1% CO2, 37°C), the
cells were washed with PBS, fixed, and stained in crystal
violet/formalin solution. The virus-induced cytopathic ef-
fect was evaluated microscopically.
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Determination of anti-EBV activity
Cord blood mononuclear cells in 24-well plates (106 cells
per well) were inoculated with cell culture supernatant con-
taining transformation-competent EBV derived from B95-8
cells (EBV B95-8) and incubated overnight. Then, the virus
was removed and 2 ml of fresh medium was added. Starting
from Day 5 the cultures were checked microscopically for
cell clusters, indicating successful transformation. Addition-
ally, transformation was confirmed by detecting EBV nu-
clear antigen (Reedman and Klein, 1973). During the cul-
ture period of 8 weeks the medium was changed once
weekly. To evaluate the influence of DSTP 27 on EBV-
induced transformation the compound was added at concen-
trations of 100, 50, and 25 g/ml 24 or 1 h before virus
infection, together with the virus as well as 1 or 24 h after
virus infection. To control the possibility of receptor block-
ade, cord blood lymphocytes were incubated with transfor-
mation-incompetent EBV derived from P3HR-1 cells (EBV
P3HR-1) before transformation-competent EBV B95-8 was
added. For quantitative evaluation microscopic photographs
were taken at Day 16 p.i. and the number of transformed
colonies were counted in a field of a size of 9  13 cm
(magnification, 180).
Anti-retrovirus assays
The anti-retroviral activity of DSTP 27 was determined
at the National Cancer Institute (NCI), Bethesda, Maryland,
by a lymphocytes killing assay (Weislow et al., 1989). In
addition to the azidothymidine-sensitive HIV-1 strains 6S,
IIIB, and RF, the following drug-resistant HIV variant
strains bearing mutations in their reverse transcriptase were
included in this study: N119 (nevirapine-resistant), DPS
(diphenyl sulfone-resistant), and A-17 (resistant to a class of
nonnucleoside reverse-transcriptase inhibitors). Further-
more, the antiviral activity against the HIV-2 strain ROD
and SIV MAC 251 was tested.
In vitro binding of DSTP 27 to heparin acrylic beads
One hundred microliters of an acrylic bead suspension
(Sigma) corresponding to 50 g immobilized heparin, was
washed three times with water and incubated with 1 ml 88
nM DSTP 27 in water. Heparin or chondroitin sulfate (CS;
from bovine trachea, Sigma) was added from a stock solu-
tion containing 100 mg/ml to the final concentrations indi-
cated and after shaking for 15 min at 20°C, DSTP 27
concentration in the supernatant was monitored at 316 nm.
In parallel experiments without acrylic beads, the effect of
heparin on UV adsorption of DSTP 27 was controlled.
Preparation of radiolabeled PrV-1112
Swine kidney cells were inoculated with PrV-1112 and
overlaid with methionine and cysteine free medium 3 h p.i.
After an additional hour, a mixture of 35S-cysteine and
35S-methionine (Translabel, ICN) was added at a concen-
tration of 200 Ci/ml. Fourty eight hours p.i. the superna-
tant was harvested and cellular debris was removed by a
low-speed centrifugation. Virus was sedimented through a
cushion of 30% sucrose in TBS and the pellet was further
purified in a step gradient of 50, 40, and 30% sucrose
(Karger et al., 1993). Purified virus was collected from the
40/50% interface and sucrose was removed by centrifuga-
tion.
Attachment assay
MDBK cells grown in 24-well tissue culture dishes were
washed with PBS-A (1% bovine serum albumin in phos-
phate-buffered saline) and cooled to 0°C on ice. All further
incubations were carried out at 0°C. For each DSTP 27
concentration tested, duplicate monolayers were incubated
with dilutions of DSTP 27 in PBS-A for 2 h, washed with
PBS-A, and then incubated with approximately 20,000 cpm
of radiolabeled purified virus in PBS-A for an additional
2 h. Unbound virus was removed by 3 washes with PBS-A,
cell monolayers with bound virus were lysed in 1% SDS,
and radioactivity was determined by liquid scintillation
counting. Amount of bound virus was expressed in percent-
age of attached virus in the absence of DSTP-27 (approxi-
mately 20% of the input virus). Table 1 represents data from
three experiments with 2 different virus preparations.
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